Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1)
Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1) Basic information
- Product Name:
- Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1)
- Synonyms:
-
- Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1)
- CZC-54252 HCl
- CZC 54252,CZC54252 hydrochloride,injury,inhibit,LRRK2,CZC54252,CZC-54252,neuronal,Leucine-rich repeat kinase 2,neuroprotective,Inhibitor,CZC 54252 hydrochloride,LRRK2-G2019S
- N-(2-((5-Chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide hydrochloride , CZC-54252 HCl
- N-(2-((5-Chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide hydrochloride
- CAS:
- 1784253-05-9
- MF:
- C22H26Cl2N6O4S
- MW:
- 541.45
- Mol File:
- 1784253-05-9.mol
Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1) Chemical Properties
- storage temp.
- -20°
- solubility
- Soluble in DMSO (up to 50 mg/ml).
- form
- solid
- color
- Off-white
- Stability:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1) Usage And Synthesis
Description
CZC-54252 HCl (1784253-05-9) is a novel, potent and selective inhibitor of the leucine-rich repeat kinase-2 (LRRK2), IC50 = 1.28 nM. Also inhibits G2019S mutant LRRK2, IC50 = 1.85 nM.1?CZC-54252 attenuates the neuronal damage elicited by the action of LRRK2 G2019S mutant in primary human neurons (EC50 = 1 nM).1 The G2019S mutant is a common mutation found in familial Parkinson’s disease patients.2?Cell permeable.
References
1) Ramsden et al. (2011), Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson’s disease-related toxicity in human neurons; ACS Chem. Biol., 6 102 2) Kramer et al. (2012), Small molecule kinase inhibitors for LRRK2 and their application to Parkinson’s disease models; ACS Chem. Neurosci., 3 151
Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1)Supplier
- Tel
- 021-QQ:65489617 15618227136
- Sales@ATKchemical.com
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Tel
- 0519-85788828 13775037613
- sales@chemrenpharm.com
- Tel
- 0371-0371-55153829 18003835034
- 2853979819@qq.com
- Tel
- 400-1647117 13681763483
- product02@bidepharm.com